

Supplementary material

Mołek-Dziadosz P, Natorska J, Malinowski KP, et al. Elevated growth differentiation factor 15 is associated with echocardiographic markers of right heart overload in atrial fibrillation. Pol Arch Intern Med. 2023; 133: 16627. doi:10.20452/pamw.16627

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Baseline characteristics and laboratory parameters of AF patients.

Variable	All patients N=241	GDF-15 <1455 pg/ml N=124	GDF-15 ≥1455 pg/ml N=116	P value
Age, year	68 (62-75.2)	67 (59-74)	72 (66-78)	<0.001
Men, n (%)	141 (58.5)	74 (59.7)	74.0 (61.2)	0.81
BMI, kg/m ²	29 (26.4-3)	30.1 (27-33.2)	28.2 (26.2-30.5)	0.002
Comorbidities and CVD risk factors, n (%)				
Hypertension	182 (75.5)	92 (74.2)	100 (82.6)	0.11
Hypercholesterolemia	144 (59.7)	70 (75.3)	74 (83.1)	0.19
Diabetes	56 (23.2)	18 (14.5)	40 (33.1)	0.002
Prior stroke	23 (9.5)	13 (10.5)	12 (9.9)	0.88
Prior MI	28 (11.6)	10 (8.06)	18 (14.9)	0.09
Previous VTE	5 (2.1)	1 (0.8)	4 (3.3)	0.17
Medications, n (%)				
Rivaroxaban	98 (40.1)	57 (46.0)	48 (39.7)	0.32
Dabigatran	93 (38.6)	43 (34.7)	50 (41.3)	0.28
Apixaban	46 (19.1)	24 (19.3)	21 (17.4)	0.56
Statin	161 (66.8)	78 (62.9)	92 (76.0)	0.03
Aspirin	27 (11.2)	12 (9.7)	15 (12.4)	0.50
Clopidogrel	18 (7.5)	9 (7.3)	9 (7.4)	0.96
ACEI	158 (65.6)	74 (59.7)	85 (70.2)	0.08
Echocardiographic parameters				
RA, cm ²	21.0 (17.0-27.0)	20.0 (16.0-25.0)	22.0 (17.7-28.0)	0.004
RV AP4Ch, mm	38.0 (33.0-42.0)	37.5 (34.0-42.7)	38.0 (34.0-42.0)	0.27
TAPSE, mm	22.0 (19.38-26.0)	22.0 (18.0- 25.0)	20.0 (17.0-24.0)	0.006
TRV max, m/s	2.5 (2.0-2.8)	2.3 (1.7-2.7)	2.7 (2.2-2.9)	0.02
RVSP, mmHg	25.6 (16.1-35)	24.9 (19-33)	28.9 (15.2-36.0)	0.63
PV Vmax, m/s	0.84 (0.7-1)	0.8 (0.7-1.0)	0.9 (0.69-1.0)	0.02
ACT, ms	110.0 (89.0-130.7)	122.0 (108.0-135.5)	100.0 (73.0-115.0)	<0.001
PT, mm	24 (21-26)	23 (21-25)	25 (20-27)	0.61
IVC	17 (15-20)	17 (14.5-19.0)	17.5 (16-23)	0.02

EF, %	55.0 (44.0-60.0)	55.0 (45.0- 62.0)	55.0 (42.0- 60.0)	0.21
LAVI, ml/m ²	44.8 (35.4-52.1)	42.0 (34.2-49.5)	46.2 (36.4-54.2)	0.11
LVEDD, mm	53.0 (48.0-65.0)	55.0 (48.0-68.0)	52.0 (47.0-60.0)	0.15
LVMI, g/m ²	123.0 (92.9-162.9)	134.9 (107.8-197.6)	113.7 (87.6-145.7)	0.24
Laboratory investigations				
WBC, 10 ³ /μl	6.8 (5.9-7.9)	6.8 (5.9-7.9)	6.7 (5.9-7.8)	0.26
Platelet count, 10 ³ /μl	204 (174.5-251.7)	207.50 (175.0-256.5)	201.0 (172.5-247.0)	0.31
Hemoglobin, g/dl	14.2 (13.3-15.1)	14.2 (13.4-15.4)	14.1 (13.1-15.0)	0.30
Glucose, mM	5.6 (5.3-6.3)	5.6 (5.3-6.1)	5.9 (5.4-6.5)	0.03
Creatinine, μM	89.0 (75.8-103.0)	85.0 (74.0- 98.0)	91.0 (76.5-108.0)	0.02
C-reactive protein, mg/l	1.7 (1-4.4)	1.8 (1.0-4.5)	1.7 (1.0-4.3)	0.31
Fibrinogen, g/l	3.2 (2.5-3.8)	3.21 (2.48-4.0)	3.21 (2.7-3.8)	0.33
P-selectin, ng/ml	36.5 (29.6-43.2)	41.68 (32.3-55.5)	41.05 (29.7-51.1)	0.33
ETP, nM x min	2027 (1757-2209)	2023 (1781- 2230)	2084 (1760-2261)	0.97
K _s , x10 ⁻⁹ cm ²	4.6 (3.7-5.5)	4.8 (4.0-5.9)	4.4 (3.69-5.1)	0.002
CLT, min	108 (98-129)	107 (96-122)	109 (101-129)	0.27

Abbreviations: AF, atrial fibrillation; MI, myocardial infarction; ACEI, angiotensin-converting enzyme inhibitors; WBC, white blood cell count; NAP-2, neutrophil-activating peptide 2; ETP, endogenous thrombin potential; TAFI, thrombin activatable fibrinolysis inhibitor; PAI-1, plasminogen activator inhibitor type 1; K_s, fibrin clot permeability; CLT, clot lysis time; RA, right atrium; RV AP4Ch, right ventricle apical four-chamber view; *TAPSE*, tricuspid annular plane systolic excursion; TRV max, maximal tricuspid regurgitation velocity; RVSP, right ventricular systolic pressure; PV Vmax, pulmonary valve maximum blood velocity, ACT, pulmonary acceleration time; PT, pulmonary trunk; IVC, inferior vena cava; EF, ejection fraction, LAVI, left atrial volume index, LVEDD, left ventricular end-diastolic diameter, LVMI, left ventricular mass index